Retrospective analysis of transarterial chemoembolization or hepatic arterial infusion chemotherapy combined with lenvatinib with or without PD-1 inhibitor as first-line therapy for unresectable hepatocellular carcinoma with high tumor burden: a prop

Triplet therapy significantly improves survival and tumor response without accelerating early liver function decline in patients with HTB-uHCC. Child-Pugh stability correlates strongly with treatment efficacy.